Roche at a Glance An Introduction to our Company. February 2013

Transcription

1 Roche at a Glance An Introduction to our Company February 2013

2 Basic facts at a glance Founded 1896 in Basel, Switzerland Founding families still hold majority stake Employing 80,000 people Currently active in 150 countries on all continents Sales 2011: 42.5 billion Swiss Francs Clear focus on healthcare Leadership in pharmaceuticals (#5)* World s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS Leadership in in vitro diagnostics (#1) and pioneer in diabetes management Unique innovation model * Source: Decision Resources, Q2/2012

3 Basic facts at a glance Focusing on innovative Pharmaceuticals and Diagnostic tests Our aim is to discover, develop and market innovative solutions that bring clear medical benefit in disease areas with high unmet medical need Oncology (e.g. breast, cervical, colon cancer) Virology (e.g. hepatitis, HIV) Inflammation and autoimmune disorders (e.g. rheumatoid arthritis, asthma) Cardiovascular and metabolic disorders (e.g. diabetes) Central Nervous System (e.g. Alzheimer's) Our products and services help to prevent, diagnose and treat diseases, thus enhancing people s health and quality of life

4 More than 116 years of Roche Historical timeline Sales in 2011: million CHF Personalised Healthcare Strategic Transition - focus on Pharmaceuticals & Diagnostics Disetronic Chugai Ventana Limited Company Diagnostics Boehringer Mannheim Genentec h Fragrances & Flavours Spin off Fragrances & Flavours Sale OTC Sale Vitamins & Fine Chemicals Founding International expansion Diversification

5 Roche Group Structure

6 Personalised Healthcare (PHC) - driver of change Key to enabling highly differentiated medicines Healthcare Pressures: Benefit-Risk Ratio Economic Pressures: Benefit-Cost Ratio New Technologies: Expanded Capabilities Need for highly differentiated medicines that positively impact public health

7 Premium for innovation Roche strategy Focused on medically differentiated therapies Pharma Dia Focus MedTech Generics OTC Differentiation

8 Biomarker to guide treatment decisions Diseases requiring sub-group identification Metastatic breast cancer 15 25% HER2 positive Asthma ~ 50% Periostin positive Non-small cell lung cancer I 10 30% EGFR positive Stomach cancer 16 22% HER2 positive Non-small cell lung cancer II ~ 50% cmet positive Metastatic melanoma ~ 50% BRAF positive

9 Roche already offers a range of examples Targeted therapies - approved Oncology Breast- and stomach cancer: Herceptin for patients with HER2-positive cancer Metastatic melanoma (skin cancer): Zelboraf for patients with BRAF-positive metastatic melanoma Lung cancer: Tarceva first-line treatment for patients with EGFR-positive non-small lung cancer Virology Hepatitis B and C infections: Pegasys (HBV) and Pegasys/Copegus (HCV), genotype and viral load testing HIV: Invirase/ Viracept/ Fuzeon, viral load testing Diagnosis Providing biomarkers and diagnostic tests

10 Our approach to Pharma innovation Diversity of approaches fueling global scale and reach Federation of >150 partners Autonomous centers Worldwide execution Genentech R&ED Product Development Pharma R&ED Chugai Diversity Research Early Dev Manufacturing Commercialisation Scale Reach Speed

11 NME submissions and their additional indications Projects currently in phase 2 and 3 onartuzumab (MetMAb) gastric cancer obinutuzumab (GA101) DLBCL PI3 kin inh (RG7321) solid tumors EGFR MAb (RG7160,GA201) solid tumors T-DM1 (RG3502) HER2-pos. mbc 1st line T-DM1 (RG3502) HER2-pos. gastric cancer mericitabine HCV MEK inhibitor ( RG7421) combo Zelboraf met melanoma obinutuzumab (GA101) inhl relapsed danoprevir HCV onartuzumab (MetMAb) mnsclc, 2 nd /3 rd line aleglitazar CV risk reduction in T2D setrobuvir HCV T-DM1 (RG3502) HER2-pos. pretreated mbc obinutuzumab (GA101) CLL bitopertin schizophrenia# ocrelizumab PPMS and RMS mglur5 (RG7090) depression Unless stated otherwise, submissions are planned to occur in US and EU. indicates a submission which has occurred with regulatory action pending # negative symptoms and sub-optimal control Status as of September 30, 2012 Oncology Immunology Virology CardioMetabolism Neuroscience Ophthalmology NME

12 Roche Values Standards that guide daily behaviour and decisions Integrity We embrace differences and are consistently open, honest, ethical and genuine. Courage We are entrepreneurial and thus take risks, reach beyond boundaries, and experiment. Passion We use our drive and commitment to energize, engage and inspire others.

13 Sustainability is integral to the way we do business Humanitarian, cultural and educating projects Phelophepa Healthcare Train in South Africa Roche Children s Walk Roche Employee Action and Charity Trust (Re&Act) Roche Commissions Roche Continents Roche n Jazz / Museum Tinguely Roche Postdoc Fellowship Programme Science programme for pupils Schweizer Jugend forscht

14 We Innovate Healthcare